Endocrine Abstracts

Background: Was performed an open study in 2 parallel groups to compare the efficacy and safety of dulaglutide and liraglutide in combination with Metformin in patients with type 2 diabetes mellitus.

Methods: Thirty-two patients (13 men and 19 women) with type 2 diabetes mellitus with unsatisfactory glycemic control on Metformin monotherapy were examined. The median age was 52 [44; 61] years old, the duration of diabetes was 4.6 [2,5; 9,0] years, median of glycated hemoglobin initially was 8.3 [7,7; 8,6] %; 14 patients were treated with dulaglutide 1.5 mg once a week, 18 patients – with liraglutide 1.2 mg every day.

Results: The duration of the observation was 26 weeks, after this period at the therapy with dulaglutide 1.5 mg/week the glycated hemoglobin descension was −1.09 [0.82, 1.21] %, which was comparable to the results in the group of patients on liraglutide 1.2 mg /day – 1.12 [0.90; 1.25] % (P=0.78). Weight loss was more significant on liraglutide – 5.2 [3.5; 6.0] kg. vs. 4.3 [2.5; 5.3] kg. on dulaglutide (P≤0.05). Side effects included nausea (35.7% for dulaglutide and 33.3% for liraglutide (P=0.9)), dyspepsia (7.1% for dulaglutide and 11.1% for liraglutide (P=0.81)), diarrhea (14.3% for dulaglutide and 11.1% for liraglutide (P=0.85)) and decreased appetite (28.6% for dulaglutide and 33.3% for liraglutide (P=0.9)). The amount of hypoglycemia was comparable in both groups and no severe hypoglycaemia was reported.

Conclusions: According to the results obtained, dulaglutide and liraglutide were comparable in effectiveness with respect to the reduction of glycated hemoglobin, while the number of side effects was comparable, but the decrease in weight on liraglutide was significantly higher than on dulaglutide.